LAUSR

747Background: Approximately 140,000 people are newly diagnosed with colorectal cancer (CRC) annually, while 50,000 will die from the disease. Median survival has increased with use of modern chemotherapy and biologic agents. Sixty percent of advanced CRC patients (pts) present with or develop liver metastases, with additional treatment options such as hepatic artery therapies. However, there is no strong scientific evidence to support the use of transarterial chemoembolization (TACE), Yttrium 90 (Y90) or chemotherapy infusion (HAI). Methods: Pooled survival analysis of 968 pts with unresectable colorectal liver metastases (CLRM) treated with hepatic artery therapies, including HAI, Y90 or TACE. A rigorous selection of studies was conducted to ensure exchangeability across studies and adequate comparison of groups. Kaplan Meier survival curves were reconstructed from original publications. Data was further stratified into presence or absence of extra-hepatic disease (EHD). Results: Total of 968 pts with m...